The companies did not provide detailed data for Tezspire, however, and William Blair’s Matt Phipps said in a note he does not ...
GlobalData on MSN6d
AstraZeneca and Amgen’s Tezspire succeeds in Phase III nasal polyps trialThe companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...
Amgen (NASDAQ:AMGN) and AstraZeneca (NASDAQ:AZN) announced Friday that their FDA-approved asthma therapy Tezspire reached ...
7d
Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients ...
Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...
Topline results from a phase 3 trial show that tezepelumab statistically significantly reduced the size of nasal polyps and nasal congestion in adults with chronic rhinosinusitis with nasal polyps ...
Dupilumab significantly improves the day-to-day symptom burden in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
Tessa Romero, an analyst from J.P. Morgan, has initiated a new Buy rating on Upstream Bio, Inc. (UPB). Tessa Romero’s rating is based on ...
▎药明康德内容团队编辑日前，阿斯利康（AstraZeneca）与安进（Amgen）合作开发的“first-in-class”单抗Tezspire（tezepelumab）针对伴有鼻息肉的慢性鼻窦炎（CRSwNP）患者进行的WAYPOINT临床3期试验 ...
The following is a summary of “Real-world effectiveness of dupilumab in a European cohort of CRSwNP (CHRINOSOR),” published in the October 2024 issue of Allergy and Immunology by Seys et al. Pivotal ...
Advancing Phase 2 clinical trials of verekitug in patients with severe asthma and CRSwNP –– Commenced startup for a Phase 2 clinical trial in ...
公开资料显示，Tezepelumab是阿斯利康与安进共同开发的一款first-in-class单克隆抗体，可抑制胸腺基质淋巴细胞生成素 (TSLP)。TSLP是一种关键的上皮细胞因子，位于多种炎症级联反应的上游，与哮喘、CRSwNP、慢性阻塞性肺疾病 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback